once daily regimen of ftc ddi efv in arv therapy na ve children n.
Download
Skip this Video
Download Presentation
Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children

Loading in 2 Seconds...

play fullscreen
1 / 16

Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children - PowerPoint PPT Presentation


  • 71 Views
  • Uploaded on

Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children. PACTG 1021. Organization. Pediatric AIDS Clinical Trials Group NIAID and NICHD sponsored Drug and expertise provided by: Triangle Pharmaceuticals – Gilead Sciences Bristol Myers Squibb. Justification.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children' - owen-strong


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
organization
Organization
  • Pediatric AIDS Clinical Trials Group
    • NIAID and NICHD sponsored
  • Drug and expertise provided by:
    • Triangle Pharmaceuticals – Gilead Sciences
    • Bristol Myers Squibb
justification
Justification
  • Once a day regimen improves compliance
  • Long half-life drugs might be more forgiving
  • Side effect profiles for all three drugs (FTC, ddI, EFV) individually are manageable
patient population
Patient Population
  • ARV Naïve (allowed perinatal prophylaxis)
  • Three cohorts, n=37:
    • 90 days to <3 years (not reported at this meeting – currently enrolling)
    • 3 years to 12 years [21 subjects]
    • 13 years to 21 years [16 volunteers]
  • Enrollment between 9/18/2001 and 10/23/2002
  • Data cut off – August 2, 2004
regimen once daily
Regimen (Once Daily)
  • FTC 6 mg/kg (maximum 200 mg)
  • ddI 240 mg/m2 (maximum 400 mg)
    • Oral suspension or ddI enteric coated beadlet capsules
  • Efavirenz – Dosing Table
    • Oral solution (30 mg/ml)
    • Capsules (50/100/200 mg)
study design
Study Design
  • Open label, Phase I-II
  • Every 4 week visits through week 96
  • Intense PK at weeks 2, 8/12, and time of discontinuation
  • Multiple spot levels drawn
  • Intention to Treat Analysis
  • Endpoints: Safety, tolerance, proportion <50 HIV copies/ml; <400 HIV copies/ml
pk result
PK Result
  • FTC and ddI pharmacokinetics provided anticipated AUCs
  • EFZ – Initial levels below anticipated for children ≤12 years receiving oral solution, so dose increased
    • Median AUCs (prior to adjustment)
adverse events
Adverse Events
  • 2 children discontinued before 2 weeks due to rash (one Grade 3, one Grade 2)
  • No subjects with laboratory abnormalities attributed to drug regimen
    • 1 Grade 4 hypoglycemia, 2 grade 3 CPK considered “possibly” related
  • 2 subjects had Grade 3 symptoms attributed to the regimen (rash; dizziness [wk1 – resolved spontaneously])
discontinuations
Discontinuations
  • 10/37 Subjects discontinued treatment
    • 2 Rashes
    • 3 Virologic failure
    • 2 Adolescents incarcerated
    • 2 Subjects felt visits were inconvenient
    • 1 Subject moved out of the country
  • No Deaths or new Category C diagnoses
conclusions
Conclusions
  • Once daily Combination of FTC/ddI/EFZ well tolerated – 2 subjects with rash
  • Efficacy appeared to be good:
    • Using ITT, 72% <50 copies at week 96
    • Only 3/37 discontinued because of viral failure
  • CD4 response was very positive: median CD4 % went from 17% to 32%
acknowledgement
Acknowledgement
  • Thank you to study volunteers and their families
  • Thank you to clinic staff of the 16 sites
pactg 1021 study team
Ross E. McKinney, Jr, M.D.

Mobeen Rathore, M.D.

Chengcheng Hu, Ph.D.

Paula Britto, M.S.

Michael Hughes, Ph.D.

Mary Elizabeth Smith, M.D.

Leslie K. Serchuk, M.D.

Joyce Kraimer, M.S.

Alberto A. Ortiz, M.S.

Linda Draper

Paul Tran, R.Ph.

Patricia Flynn, M.D.

Ram Yogev, M.D.

Stephen Spector, M.D

Coleen Cunningham, M.D.

Elaine Abrams, M.D.

Melissa Scites, R.N.

Ruth Dickover, Ph.D.

Adrianna Weinberg, M.D.

John Rodman, Pharm.D.

H. Robert Blum, Ph.D.

Gregory E. Chittick

Laurie Reynolds

PACTG 1021 Study Team